New Trade Alert: Q BioMed Inc. ($QBIO)

Date : May 15, 2019

To Get Update On Mobile Text STOCKS to 67076
The #1 Newsletter for Highly Profitable Penny Stock Alerts
our New Trade Alert Is QBIO


Today, we would like to bring to your attention a new trade opportunity.

This little known company could be positioned for incredible growth.

New Trade Alert: Q BioMed Inc. (QBIO)

Small companies often create the most impactful innovations.

In fact, larger companies need help from small companies to grow.

This is the case in many industries, but specifically in biotech.

According to Pharma Intelligence, “big pharma has long been licensing and acquiring R&D assets from outside.”

Additionally, “smaller biotechs, with new technologies and creative, focused approaches” “have proven better at discovering new drugs than large pharma.”

One of these small overlooked companies, which could have a tremendously positive impact in the biotech industry, is our new trade alert – QBIO.

QBIO is a “biotech acceleration and commercial stage company” “focused on licensing and acquiring undervalued biomedical assets in the healthcare sector.”

QBIO provides “strategic resources, developmental support and expansion capital” so that products can reach patients in need.

The company has a growing pipeline of “drug candidates with significant value in large markets of underserved patients.”

QBIO “believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets.”

One of the large markets that requires significant attention is the unfortunate development of the opiod epidemic in the US.

According to the National Institute on Drug Abuse, “every day, more than 130 people in the United States die after overdosing on opioids” while “roughly 21 to 29 percent of patients prescribed opioids for chronic pain misuse them.”

“The Centers for Disease Control and Prevention estimates that the total “economic burden” of prescription opioid misuse alone in the United States is $78.5 billion a year”.

This problem has created a new demand for non-opioid solutions for chronic pain.

As physicians curtail their use of opioids, QBIO could become more relevant than ever to investors.

The company shocked many when it recently announced: “Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare”

According to the company’s March 19th press release:

“The Company’s FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019.”

“Metastron is also approved for sale in 21 other countries.”

“In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival.”

“Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.”

But that’s not all…

In addition, QBIO has an opportunity to address the glaucoma market, which according to Bright Focus “is a leading cause of irreversible blindness in the United States and the world” with it estimated to affect “almost 80 million by 2020.”

In March, the company announced:

  • “Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington University”
  • “Q BioMed and Mannin Research to Develop GDF15 Biomarker Glaucoma Diagnostic Kit Through Collaboration with McMaster University”

But why now? Why should you care?

Most recently, in April, the company announced what could be a significant milestone:

“In a Major Breakthrough, Q BioMed Discovers First Biomarkers for Pediatric Nonverbal Autism Subgroup”

Here are the highlights from this press release:

  • “Marks the first time a company has identified biomarkers that hold the potential to stratify this subset of patients”
  • “Study examined 1,953 significant autistic biomarkers, resulting in 2 significant markers tied to expressed genes and pathways responsible for speech development”
  • “Biomarkers in the nonverbal subset were distinct from children with typical speech development with or without autism”
  • “Biomarkers will help homogenize clinical trial participants and will be studied as possible diagnostic and prognostic indicators during trials”

“Q BioMed CEO, Denis Corin highlighted, “This is a major breakthrough for these children and their families. To date, very little attention and research has been focused on these nonverbal autistic children. In partnership with the clinical and advocacy community, Q BioMed is leading the effort to better stratify this group, while also pursuing a treatment.”

According to the company:

“There are approximately 18,000-20,000 new cases of pediatric nonverbal autism in the U.S. each year and a similar amount in Europe. The majority of the children are diagnosed by the age of seven and fall within the autism spectrum. Individually, the economic costs for toddlers that become non- or minimally verbal is $10 million dollars on average per child over a lifetime.”

“Collectively, an estimated $200 billion is spent yearly on individuals who are nonverbal in the U.S. Not all individuals who are nonverbal will benefit from QBM-001. However, with validated biomarkers, testing from trained specialists and genetic testing, children who fall in this targeted population can be identified, and will have a higher likelihood of responding to an approved treatment.”

This is a potentially massive win for the company.

QBIO has a history of experiencing significant upside.

At the start of 2019 QBIO rallied from as low as 0.98 to a high of more than 2.40, experiencing gains of more than 144%.

Since this massive rally QBIO has consolidated below its 50 and 200 day moving averages (DMA) and could once again be positioned for a breakout higher.

QBIO has a 50 DMA of 1.87 and a 200 DMA of 2.04, 14% and 25% above today’s close, presenting what could be an opportunity for increased upside.

QBIO has a relative strength index (RSI) of 41, suggesting the opportunity for gains.

QBIO has experienced a remarkable 2019 thus far, announcing  multiple accomplishments.

As the company continues to execute its vision, it could present investors with significant growth potential.

Make sure to do your own due diligence.

Sources: BrightPharmaNIHPR1PR2PR3PR4PR5PR6WebsiteChart


Happy Trading!
Your Bullishguru
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term trade opportunities.
Trading Rules [Please Review Before Taking Any Action]:
  1. Do not invest more than you are willing to lose. No one likes to consider the worst case, but it’s always a risk that exists. Rule of thumb – if you cannot sleep at night as a consequence of your investment, then you have over invested.
  2. Keep calm. Do not chase. Decide for yourself if you like the trade. If you are not comfortable with the perceived risks, stay out. Timelines are to be decided by you. Approach methodically, and seek technical confirmation for direction. Always trade with a strategy in mind.
  3. Never use market orders. Only use buy and sell limit orders. Protecting your investment is more important than missing gains. Use “trailing stop %” or “trailing stop $” orders. Personally I prefer mental stops while actively managing trades rather than entering your stop into your brokerage account.
  4. Cut losses quickly when day/swing trading. It’s better to acknowledge being wrong than to have false hope. Sometimes you will be wrong in doing so, often times it will save you. It all depends on your entry.
  5. Actively manage all your investments & trade during market hours only.Trading during pre/post market hours carries greater volatility/risk.




Don’t forget to try our Free Easy-to-Use SMS service for real-time alerts and winning tips. Simply send the message STOCKS to the number 67076.

Best Regards,



This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.  The paying party may own shares and may liquidate them during the promotional period.

PLEASE NOTE WELL: & and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. & WILL NEVER ACCEPT FREE OR RESTRICTED TRADING SHARES IN ANY COMPANIES MENTIONED AT & &/OR ANY OF OUR SOCIAL NETWORKING AND EMAIL ADVERTISING PLATFORMS.

You are reading this newsletter because you have subscribed via our Opt-In Signup form on our Website. If you have been subscribed by mistake, you may unsubscribe HERE.

This Newsletter is now owned and operated by VPN Media. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our”  refers to Link Media and/or it’s subscriber base. Our website and newsletter are for entertainment purposes only. This newsletter is NOT a source of unbiased information.  Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Gains mentioned in our newsletter and on our website may be based on End of Day or intraday data. The disclaimer is to be read and fully understood before using our site, or joining our email list. Full disclaimer can be read at &

We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.

Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold &, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. & sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by & or an offer or solicitation to buy or sell any security.

COMPENSATION: & has been compensated two thousand dollars  by ALG financial via electronic transfer for a one week advertising services. & does not own any shares of QBIO
All Content, Distribution, and editorial control has been given, reviewed, and approved by ALG financial  . & does not investigate the background of any issuer or third party. They may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. & may purchase shares on the open market of any mentioned company following the dissemination of this email. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. & encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is collected from public sources only such as the profiled company’s website, news releases, and corporate filings, but has not been verified in any way to ensure the publicly available information is correct. & makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, & has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news press releases, changes in corporate structure, or changes in share structure.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead & strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. & is compliant with the Can Spam Act of 2003. & does not offer such advice or analysis, and & further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.  Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

In preparing this publication, & has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. & and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. & is not responsible for any claims made by the companies advertised herein, nor is & responsible for any other promotional firm, its program or its structure.

Copyrights 2016, All rights reserved.

Free WordPress Themes, Free Android Games